LEXICON PHARMACEUTICALS, INC. LXRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-33
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $49.8M | -$50.3M | — | -$67.9M | $107.5M |
| 2024 | $31.1M | -$200.4M | — | -$179.8M | $145.9M |
| 2023 | $1.2M | -$177.1M | — | -$162.4M | $93.1M |
| 2022 | $139,000 | -$101.9M | — | -$90.2M | $117.1M |
| 2021 | $0 | -$87.8M | — | -$88.2M | $113.6M |
| 2020 | $33,000 | -$58.6M | — | -$143.1M | $156.4M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Swain Judith L | director | 2026-06-03 | Option exercise | 89,312 | — |
| Sullivan Diane E. | director | 2026-06-03 | Option exercise | 89,312 | — |
| SOBECKI CHRISTOPHER J | director | 2026-06-03 | Option exercise | 89,312 | — |
| Cheung Ivan | director | 2026-06-03 | Option exercise | 89,312 | — |
| BARKER SAM L | director | 2026-06-03 | Option exercise | 89,312 | — |
| Amouyal Philippe | director | 2026-06-03 | Option exercise | 89,312 | — |
| DEBBANE RAYMOND | director | 2026-06-03 | Option exercise | 89,312 | — |
| Artal Participations S.a r.l. | director | 2026-04-30 | Option exercise | 20,421,735 | — |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -33 (distress)
- Working capital / assets 0.438
- Retained earnings / assets -10.907
- EBIT / assets -0.264
- Equity / liabilities 1.389
Source: SEC EDGAR filings · CIK 0001062822 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.